KHC
MYGN icon

Koesten Hirschmann & Crabtree’s Myriad Genetics MYGN Stock Holding History

Koesten Hirschmann & Crabtree’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-55
Closed -$1.51K – 209
2024
Q3 		$1.51K Hold
55
– – ﹤0.01% 168
2024
Q2 		$1.17K Hold
55
– – ﹤0.01% 193
2024
Q1 		$1.17K Buy
+55
New +$1.18K ﹤0.01% 193

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Koesten Hirschmann & Crabtree's MYGN Position: Q4 2024 in Review

Koesten Hirschmann & Crabtree sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 55 shares — an estimated $1.51K sold.

Koesten Hirschmann & Crabtree first reported a position in MYGN in Q1 2024 and held it in 3 quarters. The position peaked at $1.51K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Koesten Hirschmann & Crabtree reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Koesten Hirschmann & Crabtree sold 55 Myriad Genetics shares in Q4 2024, an estimated $1.51K.
  • Koesten Hirschmann & Crabtree first reported a position in Myriad Genetics in Q1 2024 and held it in 3 quarters.
  • Koesten Hirschmann & Crabtree's Myriad Genetics position peaked at $1.51K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Koesten Hirschmann & Crabtree's 13F filing for Q4 2024, filed 14 Feb 2025.